<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02581371</url>
  </required_header>
  <id_info>
    <org_study_id>COMRIS-ARM-C</org_study_id>
    <nct_id>NCT02581371</nct_id>
  </id_info>
  <brief_title>Comprehensive Reparative Therapy in Ischemic Stroke COMplex Repair in Ischemic Stroke-Arm</brief_title>
  <official_title>Randomized, Double-blind, Placebo-controlled Study of the Effect of Cerebrolysin® (EVER Neuro Pharma GmbH, Austria) at the Level of Paresis of the Upper Limb When Used in Complex Therapy of Acute Ischemic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinical Institute of the Brain, Russia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clinical Institute of the Brain, Russia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the present clinical phase IV study is to estimate the influence of Cerebrolysin&#xD;
      in combination with standard therapy on the dynamics of recovery of the paretic upper limb in&#xD;
      patients with acute ischemic stroke.&#xD;
&#xD;
      Each patient participates in the study for 176-190 days (approximately 6 months). The&#xD;
      estimated duration of the study is 2 years.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rehabilitation programs and drug therapy in a stroke aimed, primarily, to the stimulation of&#xD;
      the processes of neuroplasticity.&#xD;
&#xD;
      After the screening procedures the eligible patients get randomized in 1 of the 2 groups:&#xD;
      either the group of a standard therapy in combination with Cerebrolysin infusions, or the&#xD;
      group of a standard therapy in combination with placebo infusions.&#xD;
&#xD;
      The therapy consists of the 3 consecutive periods:&#xD;
&#xD;
        1. st - 10 days of daily infusions of Cerebrolysin / placebo;&#xD;
&#xD;
        2. nd - 7 days break;&#xD;
&#xD;
        3. d - 10 days of daily infusions of Cerebrolysin / placebo.&#xD;
&#xD;
      All participants will attend 7 Visits of the study (Visits 0, 1-6) at 2 sites respectively:&#xD;
&#xD;
        1. st - clinical center #1 - Sverdlovsk Regional Clinical Hospital #1, Ekaterinburg&#xD;
&#xD;
        2. nd - clinical center #2 - Clinical Institute of Brain, Ekaterinburg.&#xD;
&#xD;
      Patients will be transferred from the 1st site to the 2nd one at the moment of time between&#xD;
      Visit 2 and Visit 3.&#xD;
&#xD;
      Patients will undergo traditional laboratory and clinical examination procedures and several&#xD;
      specific ones such as scale NIHSS, modified Rankin scale, Barthel index, hand Frenchy&#xD;
      assessments. All hand Frenchy assessments will be videotaped for later evaluation by an&#xD;
      authorized researcher.&#xD;
&#xD;
      All participants will undergo the procedure of navigational transcranial magnetic stimulation&#xD;
      of the brain NBS eXimia Nexstim with the use of an individual 3D brain model created on the&#xD;
      Visit 0 MRI results basis.&#xD;
&#xD;
      Neither the patient nor the doctor will know whether they receive an investigational drug or&#xD;
      placebo.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">February 2017</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall dynamics of the hand function assessed by the Frenchay Arm Test</measure>
    <time_frame>6 months</time_frame>
    <description>Visit 5 data comparison with Visit 0 data</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dynamics of the hand function assessed by the Frenchay Arm Test</measure>
    <time_frame>6 months</time_frame>
    <description>Visits 2,3,4 data comparison with Visit 0 data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dynamics of the grades on the NIHSS scale</measure>
    <time_frame>6 months</time_frame>
    <description>Visits 2,3,4,5 data comparison with Visit 0 data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dynamics of the grades on the modified Rankin scale</measure>
    <time_frame>6 months</time_frame>
    <description>Visits 2,3,4,5 data comparison with Visit 0 data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dynamics of the Barthel index changes</measure>
    <time_frame>6 months</time_frame>
    <description>Visits 2,3,4,5 data comparison with Visit 0 data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dynamics of the cerebral infarction volume decrease according the 3D MRI data</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dynamics of the hemispheres cortex topology of palms motor centers according to navigated transcranial stimulation of the brain (NBS)</measure>
    <time_frame>6 months</time_frame>
    <description>Visit 4, 5 data comparison with Visit 3 data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dynamics of motor response threshold based on the results of navigated transcranial stimulation of the brain (NBS)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dynamics of the amplitude of motor responses</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dynamics of the latency of motor responses</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency, nature and severity of adverse events.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Cerebrolysin infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cerebrolysin, solution for injection, 10 ml vials. Two 10-day courses of 50 ml of investigational drug + 50 ml of sodium chloride 0.9% iv slowly drip infusions daily, separated with a 7-day interval</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo infusion</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sodium chloride 0.9%, solution for infusion, 100 ml. Two 10-day courses of 100 ml of sodium chloride 0.9% iv slowly drip daily, separated with a 7-day interval.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cerebrolysin infusion</intervention_name>
    <description>Two 10-day courses of 50 ml of investigational drug + 50 ml of sodium chloride 0.9% iv slowly drip infusions daily, separated with a 7-day interval</description>
    <arm_group_label>Cerebrolysin infusion</arm_group_label>
    <other_name>Cerebrolysin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo infusion</intervention_name>
    <description>Two 10-day courses of 100 ml of sodium chloride 0.9% iv slowly drip daily, separated with a 7-day interval</description>
    <arm_group_label>Placebo infusion</arm_group_label>
    <other_name>sodium chloride</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          1. A signed patient informed consent;&#xD;
&#xD;
          2. Men and women at the age from 45 years to 75 years, inclusive;&#xD;
&#xD;
          3. Confirmed (clinically and by MRI of the brain) diagnosis of acute ischemic stroke in&#xD;
             the basin of the middle cerebral artery;&#xD;
&#xD;
          4. The severity of the stroke from 5 to 24 points on a scale NIHSS;&#xD;
&#xD;
          5. Hemiparesis, mainly affecting the upper limbs (not more than 2 points in the&#xD;
             evaluation function of the affected hand using the test for hand Frenchay and not more&#xD;
             than 2 points in the evaluation of the affected lower limb 6-point scale NIHSS);&#xD;
&#xD;
          6. The time from the onset of the disease prior to the introduction of the drug for 72&#xD;
             hours;&#xD;
&#xD;
          7. The willingness of patients of both sexes and their sexual partners with preserved&#xD;
             reproductive function to use reliable methods of contraception, starting from the&#xD;
             moment of inclusion in the study until the completion of participation in this&#xD;
             clinical study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The age of 45 years or older than 75 years;&#xD;
&#xD;
          2. Known intolerance (including allergic reactions) Cerebrolysin, excipients of the&#xD;
             investigational medication;&#xD;
&#xD;
          3. Thrombolytic therapy;&#xD;
&#xD;
          4. Signs of a hemorrhagic stroke;&#xD;
&#xD;
          5. Impairment of consciousness (≥ 2 points during the evaluation under item 1A NIHSS);&#xD;
&#xD;
          6. The presence of elements allowing to predict the resolution of neurological symptoms&#xD;
             within 24 hours from the first symptoms;&#xD;
&#xD;
          7. Stroke or transient ischemic attack in history;&#xD;
&#xD;
          8. The score on the modified Rankin scale to a stroke more than 0 points;&#xD;
&#xD;
          9. Concomitant therapy or neuroprotective nootropic drugs;&#xD;
&#xD;
         10. New-onset seizures or epilepsy;&#xD;
&#xD;
         11. Planned carotid endarterectomy or other operations for secondary prevention of stroke;&#xD;
&#xD;
         12. Neurological disease or pathology of the neuromuscular system or any other disease&#xD;
             that may affect the interpretation of study results;&#xD;
&#xD;
         13. Systemic therapy with biological drugs, including interferon, inductors and/or&#xD;
             cytokine/anti-cytokine (e.g., anti-TNF, anti-CD4, IL-10, IL-1, etc.) within 1 month&#xD;
             prior to screening;&#xD;
&#xD;
         14. Severe concomitant diseases, including cancer, which, in the opinion of the&#xD;
             investigator, may affect the estimated parameters;&#xD;
&#xD;
         15. Uncontrolled hypertension (SBP ≥ 220 mm Hg. CL. and/or DBP ≥ 120 mm Hg. article in&#xD;
             repeated measurements at the screening visit);&#xD;
&#xD;
         16. Uncontrolled angina, congestive heart failure or severe arrhythmia;&#xD;
&#xD;
         17. The presence of chronic infection (hepatitis B, C or AIDS) in the active form.&#xD;
&#xD;
         18. Severely impaired renal function or hepatic impairment (total bilirubin no more than&#xD;
             1.5 hvgn, the level of serum creatinine no more than 2.5 hugn and the levels of ALT,&#xD;
             AST, GGT is not higher than 2.5 hvgn);&#xD;
&#xD;
         19. Diseases of the blood;&#xD;
&#xD;
         20. Mental illness, severe depression or suicide attempts in history;&#xD;
&#xD;
         21. The a history of drug addiction, alcoholism and abuse of drugs;&#xD;
&#xD;
         22. Contraindications to MRI: metal body, splinters, ferromagnetic implants (pacemakers,&#xD;
             automatic dosing of drugs, implanted insulin pumps, artificial anus with a magnetic&#xD;
             closure, artificial heart valves with metal elements), steel implants (clamps/clips on&#xD;
             blood vessels, artificial joints, metal osteosynthesis devices), hearing AIDS;&#xD;
&#xD;
         23. Participation in any other clinical study within 30 days prior to screening or&#xD;
             simultaneous participation in other clinical studies;&#xD;
&#xD;
         24. Pregnancy, breastfeeding or planning a pregnancy;&#xD;
&#xD;
         25. Women and men with preserved reproductive potential who refuse to use effective&#xD;
             methods of contraception throughout the study;&#xD;
&#xD;
         26. Life expectancy less than 1 year;&#xD;
&#xD;
         27. Any disease or circumstances that, in the opinion of the investigator, may interfere&#xD;
             with the subject participating in the study or in relation to which participation in&#xD;
             the study may be dangerous for the subject;&#xD;
&#xD;
        Premature withdrowal criteria:&#xD;
&#xD;
          1. The research subject may discontinue participation at any time without giving a&#xD;
             reason;&#xD;
&#xD;
          2. The researcher ahead of time to exclude the patient from the study in the following&#xD;
             cases;&#xD;
&#xD;
          3. The refusal of the subject from further participation in the study;&#xD;
&#xD;
          4. Failure to comply with the subject rules of participation in the study;&#xD;
&#xD;
          5. The reasons that emerged during the study and threatening the security of the subject,&#xD;
             including those associated with taking study medication adverse events;&#xD;
&#xD;
          6. The entities with during the study pregnancy;&#xD;
&#xD;
          7. The application of the patient in the study period of any additional neuroprotective&#xD;
             and nootropic drugs, drugs from the group of correctors of cerebral blood flow;&#xD;
&#xD;
          8. Other reasons arising in the course of the study and prevent the realization of the&#xD;
             study according to the Protocol;&#xD;
&#xD;
          9. Repeated stroke in the course of the study;&#xD;
&#xD;
         10. Subjects who are lost to observation, also belong to prematurely withdrawn from the&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrey Avgustovich Belkin, Prof.,MD,PhD</last_name>
    <role>Study Director</role>
    <affiliation>Clinical Institute of Brain</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrey Avgustovich Belkin, Prof.,MD,PhD</last_name>
    <phone>(343) 311-3381</phone>
    <email>clinic@neuro-clinic.ru</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andrey Marisovich Alasheev, MD, PhD</last_name>
    <phone>(343) 351-1535</phone>
    <email>director@sciencefiles.ru</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinical Institute of Brain</name>
      <address>
        <city>Beryozovsky</city>
        <state>Sverdlovsk region</state>
        <zip>620102</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrey Avgustovich Belkin, Prof.,MD,PhD</last_name>
      <phone>(343) 311-3381</phone>
      <email>clinic@neuro-clinic.ru</email>
    </contact>
    <investigator>
      <last_name>Andrey Avgustovich Belkin, Prof.,MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sverdlovsk Regional Clinical Hospital #1</name>
      <address>
        <city>Ekaterinburg</city>
        <state>Sverdlovsk region</state>
        <zip>620102</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrey Marisovich Alasheev, MD, PhD</last_name>
      <phone>+7(905)800-43-02</phone>
      <email>director@sciencefiles.com</email>
    </contact>
    <investigator>
      <last_name>Andrey Marisovich Alasheev, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <link>
    <url>http://www.neuro-ural.ru/</url>
    <description>Clinical Institute of Brain. Official website</description>
  </link>
  <link>
    <url>http://www.okb1.ru</url>
    <description>Sverdlovsk Regional Clinical Hospital #1. Official website</description>
  </link>
  <verification_date>October 2015</verification_date>
  <study_first_submitted>October 19, 2015</study_first_submitted>
  <study_first_submitted_qc>October 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2015</study_first_posted>
  <last_update_submitted>October 19, 2015</last_update_submitted>
  <last_update_submitted_qc>October 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cerebrolysin</keyword>
  <keyword>neuroplasticity</keyword>
  <keyword>upper limb</keyword>
  <keyword>middle cerebral artery</keyword>
  <keyword>NBS</keyword>
  <keyword>navigation brain stimulation</keyword>
  <keyword>paretic limb</keyword>
  <keyword>stroke</keyword>
  <keyword>ischemic stroke</keyword>
  <keyword>rehabilitation</keyword>
  <keyword>Frenchay Arm Test</keyword>
  <keyword>NBS eXimia Nexstim</keyword>
  <keyword>Barthel index</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cerebrolysin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

